CoChat

VX-548 in the treatment of acute pain

Open access
Hang Kong, Aaron Yik, Tan, Hon Sen, Habib, Ashraf S · 2024 · Pain Management

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Acute pain management requires balancing analgesia with adverse effects risk. The voltage-gated sodium channel NaV1.8 plays an important role in pain physiology, and its inhibition was shown to have analgesic effects. VX-548 is a new oral NaV1.8-specific inhibitor that received United States Food and Drug Administration Fast Track and Breakthrough Therapy designations. Its efficacy was demonstrated in two Phase II trials of patients who underwent abdominoplasty and bunionectomy. These showed that VX-548, when given as an oral loading dose of 100 mg followed by 50 mg 12-hly, significantly decreased pain scores compared with placebo. Similarly, two Phase III trials of patients who underwent abdominoplasty and bunionectomy comparing VX-548 with hydrocodone bitartrate-acetaminophen and placebo reported significantly reduced pain scores compared with placebo, but no improvement compared with hydrocodone bitartrate-acetaminophen. Evidence from Phase II and III trials suggest that VX-548 is well-tolerated, with headache, nausea, constipation and dizziness being the most common adverse effects. However, the safety of prolonged VX-548 administration is uncertain; a Phase II trial of patients with diabetic neuropathy who received high-dose VX-548 over 12 weeks reported decreased creatinine clearance. Data pertaining to VX-548 safety and efficacy within the context of multimodal analgesia and pregnancy are also needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/17581869.2024.2421749

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Jones J, Corral DJ, Lechner SM, et al. Selective Inhibition of NaV1.8 with VX-548 for Acute Pain. N Engl J Med. 2023;789:401.

Cited by

See all 44

Metadata

Authors
Hang Kong, A. Y., Tan, H. S., & Habib, A. S.
Affiliations
  • Department of Women's Anesthesia
  • KK Women's and Children's Hospital (SG)
  • Duke University (US)
Corresponding author
Habib, Ashraf S
Venue
Pain Management
Published
2024-09
Volume
14
Issue
9
Pages
477-486
ISSN
  • 1758-1869 (ISSN-L)
  • 1758-1877
OpenAlex
W4404474219
Cited by
31
References
32
Citations by year
2026: 14 · 2025: 17
FWCI
3.43
Type
journal article
Language
en
Open access
Locations
  • Pain Management (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Topics
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Anesthesia and Pain Management
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
Keywords
Nav1.8, acute pain management, postoperative pain, abdominoplasty, bunionectomy, hydrocodone/acetaminophen, analgesic efficacy, adverse effects, diabetic neuropathy, creatinine clearance, multimodal analgesia, pregnancy safety
MeSH terms
Humans, Spiro Compounds, Thiophenes, Acute Pain, Voltage-Gated Sodium Channel Blockers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: VX-548 in the treatment of acute pain. https://app.cochat.ai/papers/10.1080/17581869.2024.2421749
The paper
Hang Kong, A. Y., Tan, H. S., & Habib, A. S. (2024). VX-548 in the treatment of acute pain. Pain Management. https://doi.org/10.1080/17581869.2024.2421749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.